|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||28.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Why Pfizer, Novartis, and Sanofi rank at the top of all dividend stocks in the generic-drug industry.
Novartis has announced plans to lay off around 250 employees in the U.S. and another 500 overseas, but the Swiss drug giant’s Massachusetts operations are being spared — for the most part. It comes just days after Novartis said it will eliminate 500 positions in Basel, Switzerland, while adding 350 “high-tech” roles there focused on biologics development and production. The company’s Massachusetts operations are largely avoiding the chopping block, however.
Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.